This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (142)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Quality of Care  • Evidence-Based Medicine  • Review  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis

Nhi-Ha Trinh, MD, MPH; Jennifer Hoblyn, MB, MRCPsych, MPH; Subhanjoy Mohanty, PhD; Kristine Yaffe, MD

JAMA. 2003;289:210-216.

Context  Cholinesterase inhibitors are the primary treatment for the cognitive symptoms of Alzheimer disease (AD). Cholinergic dysfunction is also associated with neuropsychiatric and functional deficits, but results from randomized controlled trials of cholinesterase inhibitors are conflicting.

Objective  To conduct a systematic review and meta-analysis to quantify the efficacy of cholinesterase inhibitors for neuropsychiatric and functional outcomes in patients with mild to moderate AD.

Data Sources  We performed a literature search of trials using MEDLINE (January 1966–December 2001), Dissertations Abstracts On-line, PSYCHINFO, BIOSIS, PubMed, and the Cochrane Controlled Trials Register. We retrieved English- and non–English-language articles for review and collected references from bibliographies of reviews, original research articles, and other articles of interest. We searched for both published and unpublished trials, contacting researchers and pharmaceutical companies.

Study Selection  We included 29 parallel-group or crossover randomized, double-blind, placebo-controlled trials of outpatients who were diagnosed as having mild to moderate probable AD and were treated for at least 1 month with a cholinesterase inhibitor. Sixteen trials included neuropsychiatric and 18 included functional measures.

Data Extraction  Two investigators (N.H.T. and J.H.) independently extracted study methods, sources of bias, and outcomes. Neuropsychiatric outcomes were measured with the Neuropsychiatric Inventory (NPI, 0-120 points) and the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog, 0-50 points) and were analyzed with the weighted mean difference method. Functional outcomes were measured with several activities of daily living (ADL) and instrumental activities of daily living (IADL) scales and analyzed with the standardized mean difference method.

Data Synthesis  For neuropsychiatric outcomes, 10 trials included the ADAS-noncog and 6 included the NPI. Compared with placebo, patients randomized to cholinesterase inhibitors improved 1.72 points on the NPI (95% confidence interval [CI], 0.87-2.57 points), and 0.03 points on the ADAS-noncog (95% CI, 0.00-0.05 points). For functional outcomes, 14 trials used ADL and 13 trials used IADL scales. Compared with placebo, patients randomized to cholinesterase inhibitors improved 0.1 SDs on ADL scales (95% CI, 0.00-0.19 SDs), and 0.09 SDs on IADL scales (95% CI, 0.01 to 0.17 SDs). There was no difference in efficacy among various cholinesterase inhibitors.

Conclusions  These results indicate that cholinesterase inhibitors have a modest beneficial impact on neuropsychiatric and functional outcomes for patients with AD. Future research should focus on how such improvements translate into long-term outcomes such as patient quality of life, institutionalization, and caregiver burden.

Author Affiliations: Department of Psychiatry, Massachusetts General Hospital, Boston (Dr Trinh); Veterans Affairs Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif (Dr Hoblyn); Center for Astrophysics, Harvard University, Boston (Dr Mohanty); and Departments of Psychiatry, Neurology, and Epidemiology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, Calif (Dr Yaffe).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Cholinesterase Inhibitors for Alzheimer Disease
Willem A. van Gool and Afina W. Lemstra
JAMA. 2003;289(18):2359.
EXTRACT | FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Thomas E. Finucane
JAMA. 2003;289(18):2359.
EXTRACT | FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Lon S. Schneider
JAMA. 2003;289(18):2359-2360.
EXTRACT | FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Sean Lilienfeld
JAMA. 2003;289(18):2360.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cholinergic Stimulation Enhances Neural Activity Associated with Encoding but Reduces Neural Activity Associated with Retrieval in Humans
Kukolja et al.
J. Neurosci. 2009;29:8119-8128.
ABSTRACT | FULL TEXT  

Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?
Schoenmakers et al.
Fam Pract 2009;0:cmp024v1-cmp024.
ABSTRACT | FULL TEXT  

Review: Therapy for Alzheimer's disease: how effective are current treatments?
Lanctot et al.
Therapeutic Advances in Neurological Disorders 2009;2:163-180.
ABSTRACT  

Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty
Leibing
Transcultural Psychiatry 2009;46:180-206.
ABSTRACT  

Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection
Buckingham et al.
Pharmacol. Rev. 2009;61:39-61.
ABSTRACT | FULL TEXT  

Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease
Tangwongchai et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2009;23:593-601.
ABSTRACT  

Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial
Sultzer et al.
Am. J. Psychiatry 2008;165:844-854.
ABSTRACT | FULL TEXT  

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Raina et al.
ANN INTERN MED 2008;148:379-397.
ABSTRACT | FULL TEXT  

Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis
Maidment et al.
The Annals of Pharmacotherapy 2008;42:32-38.
ABSTRACT | FULL TEXT  

Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard et al.
NEJM 2007;357:1382-1392.
ABSTRACT | FULL TEXT  

Treatment of Neuropsychiatric Symptoms in Patients with Dementia
Yaffe
NEJM 2007;357:1441-1443.
FULL TEXT  

Dementia and Comorbidities: An Overview of Diagnosis and Management
Swanson and Carnahan
Journal of Pharmacy Practice 2007;20:296-317.
ABSTRACT  

Sufficiently Important Difference for Common Cold: Severity Reduction
Barrett et al.
Ann Fam Med 2007;5:216-223.
ABSTRACT | FULL TEXT  

Cognitive and Psychopathologic Response to Rivastigmine in Dementia With Lewy Bodies Compared to Alzheimer's Disease: A Case Control Study
Rozzini et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2007;22:42-47.
ABSTRACT  

Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Blaszczyk and Mathys
Journal of Pharmacy Practice 2007;20:13-28.
ABSTRACT  

Research Agenda for DSM-V: Diagnostic Categories and Criteria for Neuropsychiatric Syndromes in Dementia
Jeste et al.
J Geriatr Psychiatry Neurol 2006;19:160-171.
ABSTRACT  

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings et al.
Neurology 2006;67:57-63.
ABSTRACT | FULL TEXT  

Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial.
Callahan et al.
JAMA 2006;295:2148-2157.
ABSTRACT | FULL TEXT  

Innovations: Geriatric Psychiatry: Diagnosis and Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease
Lavretsky and Nguyen
Psychiatr. Serv. 2006;57:617-619.
ABSTRACT | FULL TEXT  

Questioning the evidence.
Keren
CMAJ 2006;174:1304-1305.
FULL TEXT  

Appeals System and Its Outcomes in National Health Insurance in Taiwan
Lin et al.
The Annals of Pharmacotherapy 2006;40:506-511.
ABSTRACT | FULL TEXT  

Medication use to treat memory loss in dementia: Perspectives of persons with dementia and their caregivers
Lindstrom et al.
Dementia 2006;5:27-50.
ABSTRACT  

A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia
Huey et al.
Neurology 2006;66:17-22.
ABSTRACT | FULL TEXT  

Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study
Goekoop et al.
Brain 2006;129:141-157.
ABSTRACT | FULL TEXT  

Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial
ONDER et al.
Br. J. Psychiatry 2005;187:450-455.
ABSTRACT | FULL TEXT  

Rivastigmine: An Open-Label Observational Study of Behavioral Symptoms Identified as Most Troubling by Caregivers of Patients With Alzheimer's Disease
Lilly and Farlow
J Am Psychiatr Nurses Assoc 2005;11:293-297.
ABSTRACT  

Cholinesterase inhibitor use in geriatric outpatients with dementia
Linnebur and Ruscin
Am J Health Syst Pharm 2005;62:923-926.
FULL TEXT  

Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink et al.
JAMA 2005;293:596-608.
ABSTRACT | FULL TEXT  

Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease
Standridge
Evid. Based Ment. Health 2004;7:112-112.
FULL TEXT  

Donepezil therapy for neuropsychiatric symptoms in AD: Methods make the message
Herrmann and Knopman
Neurology 2004;63:200-201.
FULL TEXT  

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Holmes et al.
Neurology 2004;63:214-219.
ABSTRACT | FULL TEXT  

Forgotten Frontal Lobe Syndrome or "Executive Dysfunction Syndrome"
Lyketsos et al.
Psychosomatics 2004;45:247-255.
FULL TEXT  

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood
J. Neurol. Neurosurg. Psychiatry 2004;75:677-685.
ABSTRACT | FULL TEXT  

Delirium and Dementia
Ajilore and Kumar
Focus 2004;2:210-220.
ABSTRACT | FULL TEXT  

Donepezil is somewhat effective for Alzheimer's, probably better than galantamine
BMJ 2004;328:0-0.
FULL TEXT  

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
Lanctot et al.
CMAJ 2003;169:557-564.
ABSTRACT | FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
van Gool and Lemstra
JAMA 2003;289:2359-2359.
FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Lilienfeld
JAMA 2003;289:2360-2360.
FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Finucane
JAMA 2003;289:2359-2359.
FULL TEXT  

Cholinesterase Inhibitors for Alzheimer Disease
Schneider
JAMA 2003;289:2359-2360.
FULL TEXT  

Modest Benefit for Cholinesterase Inhibitors in Alzheimer's Patients
JWatch Psychiatry 2003;2003:10-10.
FULL TEXT  

Alzheimer's Drugs May Offer Psychiatric Benefits
Rosack
Psychiatr. News 2003;38:26-26.
FULL TEXT  

Modest Benefit for Cholinesterase Inhibitors in Alzheimer's Patients
JWatch General 2003;2003:3-3.
FULL TEXT